news
Experimental mAb subdues type 1 diabetes in laboratory mice
A monoclonal antibody given to mice reversed type 1 diabetes by suppressing the actions of glucagon, a study has shown.
List view / Grid view
Antibodies
article
Advancing neutralising antibody therapies for COVID-19
In this article, Ian Chan, Chief Executive Officer and Co-Founder of biotech company Abpro, discusses the development of neutralising antibodies for SARS-CoV-2. Abpro’s neutralising antibody candidate ABP 300 is currently in Phase II/III trials.
article
SARS-CoV-2 and immunology: antibody developments
Discover the latest in SARS-CoV-2 antibody research as we cover three of the most recent developments in this article.
whitepaper
ebook: Vaccines in the digital age
In this ebook, we’ll see how digitally enabling your organisation can increase capacity and improve vaccine production.
news
Novel DNA-based COVID-19 vaccines induce immune responses in mice
The DREP-S vaccine candidate was found to be the most potent of the two investigational vaccine prototypes, eliciting high titers of SARS-CoV-2 neutralising antibodies after a single dose.
news
New COVID-19 vaccine elicits strong protective immunity in mice and monkeys
A new MVA-based vaccine has shown success at inducing COVID-19 antibody and T-cell responses in pre-clinical studies.
news
COVID-19 vaccine candidate stimulates neutralising antibody production in vivo
The novel haptenised SARS-CoV-2 s-Spike vaccine, BVX-0320, stimulated mice to create neutralising antibodies that were able to reduce SARS-CoV-2 plaques in a neutralisation test.
news
Majority retain COVID-19 antibodies for six months after infection
A study has shown that 88 percent of people infected by COVID-19 were able to produce SARS-CoV-2 antibodies after six months.
news
N439K variant of SARS-CoV-2 is resistant to some neutralising antibodies, shows study
The N439K mutation improves the interaction between SARS-CoV-2 Spike protein and the viral receptor ACE2 and eludes antibody-mediated immunity, say investigators.
news
Altering balance of fibroblasts could prevent spread of colorectal cancer
Researchers have found that colorectal cancer-associated fibroblasts can be altered using a gremlin 1-neutralising antibody or by overexpressing meflin.
whitepaper
Whitepaper: Why BioPharma Lifecycle Management?
In this whitepaper we explore some of the major bottlenecks in the development lifecycle and the current barriers to effective digital transformation.
whitepaper
Application note: Automated Simple Westerns in targeted protein degradation
Learn how Simple Western automated immunoassays screen degraders and IMiD compounds to quantify degradation activity, providing accurate DC50 and Dmax values.
news
Novel antibody candidate could offer pan-coronavirus protection
The lead candidate, ADG2, was able to neutralise SARS-CoV and various strains of SARS-CoV-2, including those that are resistant to currently available antibody treatments.
news
NSAIDs could be damaging to COVID-19 patients, dependent on timing, suggests study
In murine models of COVID-19, researchers found that non-steroidal anti-inflammatory drugs (NSAIDs) can suppress the inflammatory response and production of antibodies.
news
Rhesus macaques with SARS-CoV-2 develop promising immune response
A study has shown that the immune response of rhesus macaques with SARS-CoV-2 could be reproduced with a vaccine.